<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092621</url>
  </required_header>
  <id_info>
    <org_study_id>19-106</org_study_id>
    <nct_id>NCT04092621</nct_id>
  </id_info>
  <brief_title>Rapid Atrial Fibrillation Treatment Strategy</brief_title>
  <acronym>RAFTS</acronym>
  <official_title>Rapid Atrial Fibrillation Treatment Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Our Lady of the Lake Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Our Lady of the Lake Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, open-label clinical trial studying the treatment of new onset atrial
      fibrillation in critically ill patients with septic shock. Patients will be assigned to
      rhythm vs rate control strategies with various outcome measures assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data have demonstrated that critically ill patients with septic shock who develop atrial
      fibrillation suffer a greater likelihood of death and other complications when compared with
      patients who remain in sinus rhythm, however, little evidence exists to inform treatment
      strategies in this population. Ours is a pilot study evaluating rhythm vs rate control
      strategies in patients with septic shock and respiratory failure requiring invasive
      mechanical ventilation who develop new onset atrial fibrillation (NOAF). Design will be
      prospective, randomized, open-label. Patients in the rhythm control arm will receive IV
      amiodarone infusion followed by attempt at electrical cardioversion within 24 hours
      development of NOAF. Those in the rate control arm will receive negative chronotropic agents
      (beta blockers, calcium channel blockers, amiodarone, or digoxin) at the discretion of the
      treating physician. Available patient data will be collected for a total of 180 days
      following enrollment, and outcomes assessed will include ICU length of stay, ventilator free
      days, and time on vasopressors
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 16, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICU Length of Stay (LOS)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days patient was in the ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Days alive and free from mechanical ventilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasopressor days</measure>
    <time_frame>28 days</time_frame>
    <description>If vasopressors are administered, number of days patient received vasopressors in the ICU</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>New Onset Atrial Fibrillation</condition>
  <condition>Sepsis</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Rhythm-control strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rate-control strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone in Parenteral Dosage Form</intervention_name>
    <description>Amiodarone IV</description>
    <arm_group_label>Rhythm-control strategy</arm_group_label>
    <other_name>Cordarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone Pill</intervention_name>
    <description>Amiodarone tablet</description>
    <arm_group_label>Rhythm-control strategy</arm_group_label>
    <other_name>Cordarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Direct Current Cardioversion (DCC)</intervention_name>
    <description>Convert arrhythmia back to sinus rhythm</description>
    <arm_group_label>Rhythm-control strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rate-control therapy</intervention_name>
    <description>one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin</description>
    <arm_group_label>Rate-control strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No history of atrial fibrillation

          -  Meet Sepsis-3 criteria

          -  New onset atrial fibrillation in the ICU

          -  Atrial fibrillation treatment warranted

          -  Anticoagulation therapy not contraindicated

          -  On a ventilator

          -  Patient or family member willing to provide informed consent to participate in study

        Exclusion Criteria:

          -  Post-cardiac or thoracic surgery

          -  Hemodynamically unstable

          -  Unable to tolerate anticoagulation

          -  Physician provider does not agree for patient to participate in study

          -  Patient or family member unwilling or unable to provide informed consent

          -  Expected death within 24 hours

          -  Non-English speakers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hollis R O'Neal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana State University Health Sciences Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hollis R O'Neal, MD</last_name>
    <phone>2253812755</phone>
    <email>honeal@lsuhsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hollis R O'Neal, MD</last_name>
      <phone>225-381-2755</phone>
      <email>honeal@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth C Civello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omid Baniahmad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bögelein D, Gauss A, Georgieff M, Stahl W. Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational study. Crit Care. 2010;14(3):R108. doi: 10.1186/cc9057. Epub 2010 Jun 10.</citation>
    <PMID>20537138</PMID>
  </reference>
  <reference>
    <citation>Yoshida T, Fujii T, Uchino S, Takinami M. Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review. J Intensive Care. 2015 Apr 23;3(1):19. doi: 10.1186/s40560-015-0085-4. eCollection 2015.</citation>
    <PMID>25914828</PMID>
  </reference>
  <reference>
    <citation>Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis. 2012 Apr;105(4):226-38. doi: 10.1016/j.acvd.2011.11.005. Epub 2012 Jan 21. Review.</citation>
    <PMID>22633297</PMID>
  </reference>
  <reference>
    <citation>Chean CS, McAuley D, Gordon A, Welters ID. Current practice in the management of new-onset atrial fibrillation in critically ill patients: a UK-wide survey. PeerJ. 2017 Sep 8;5:e3716. doi: 10.7717/peerj.3716. eCollection 2017.</citation>
    <PMID>28929012</PMID>
  </reference>
  <reference>
    <citation>Sibley S, Muscedere J. New-onset atrial fibrillation in critically ill patients. Can Respir J. 2015 May-Jun;22(3):179-82. Review.</citation>
    <PMID>26057373</PMID>
  </reference>
  <reference>
    <citation>Walkey AJ, Hogarth DK, Lip GYH. Optimizing atrial fibrillation management: from ICU and beyond. Chest. 2015 Oct;148(4):859-864. doi: 10.1378/chest.15-0358. Review.</citation>
    <PMID>25951122</PMID>
  </reference>
  <reference>
    <citation>Kanji S, Williamson DR, Yaghchi BM, Albert M, McIntyre L; Canadian Critical Care Trials Group. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care. 2012 Jun;27(3):326.e1-8. doi: 10.1016/j.jcrc.2011.10.011. Epub 2012 Jan 4.</citation>
    <PMID>22226423</PMID>
  </reference>
  <reference>
    <citation>Mayr A, Ritsch N, Knotzer H, Dünser M, Schobersberger W, Ulmer H, Mutz N, Hasibeder W. Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. Crit Care Med. 2003 Feb;31(2):401-5.</citation>
    <PMID>12576943</PMID>
  </reference>
  <reference>
    <citation>Walkey AJ, Greiner MA, Heckbert SR, Jensen PN, Piccini JP, Sinner MF, Curtis LH, Benjamin EJ. Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J. 2013 Jun;165(6):949-955.e3. doi: 10.1016/j.ahj.2013.03.020. Epub 2013 Apr 25.</citation>
    <PMID>23708166</PMID>
  </reference>
  <reference>
    <citation>Arrigo M, Jaeger N, Seifert B, Spahn DR, Bettex D, Rudiger A. Disappointing Success of Electrical Cardioversion for New-Onset Atrial Fibrillation in Cardiosurgical ICU Patients. Crit Care Med. 2015 Nov;43(11):2354-9. doi: 10.1097/CCM.0000000000001257.</citation>
    <PMID>26468695</PMID>
  </reference>
  <reference>
    <citation>Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 2011 Nov 23;306(20):2248-54. doi: 10.1001/jama.2011.1615. Epub 2011 Nov 13.</citation>
    <PMID>22081378</PMID>
  </reference>
  <results_reference>
    <citation>Liu WC, Lin WY, Lin CS, Huang HB, Lin TC, Cheng SM, Yang SP, Lin JC, Lin WS. Prognostic impact of restored sinus rhythm in patients with sepsis and new-onset atrial fibrillation. Crit Care. 2016 Nov 18;20(1):373.</citation>
    <PMID>27855722</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Our Lady of the Lake Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Hollis O Neal</investigator_full_name>
    <investigator_title>Medical Director of Research</investigator_title>
  </responsible_party>
  <keyword>new onsent atrial fibrillation</keyword>
  <keyword>sepsis</keyword>
  <keyword>critical care</keyword>
  <keyword>direct current cardioversion</keyword>
  <keyword>atrial fibrillation treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

